Plain-English translation of NCT07022470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a shorter course of internal radiation therapy (called brachytherapy) can work just as well as the standard treatment for advanced cervical cancer. Normally patients receive four doses, but this study investigates whether three doses might be enough for some patients while still delivering effective treatment and minimizing side effects.
Shorter treatment courses could reduce the burden on patients by requiring fewer hospital visits and less time away from work and family, while still controlling the cancer effectively. Researchers want to know if this new approach is safe and feasible without compromising treatment outcomes.
You likely qualify if…
You likely don't qualify if…
When you come for your first internal radiation session, your doctors will use imaging scans to check whether you meet specific criteria for receiving three doses instead of four. If you do, you'll receive the shorter three-dose treatment plan; if not, you'll receive the standard four-dose treatment. Either way, you'll be closely monitored throughout your treatment to ensure it's working safely and effectively.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Stanford University
Enrollment target
~41 participants
Started
June 2025
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alyssa Yauger
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.